Daily News Watch

News Home Page

Access the 15 most recent news items below. For older items, please click the 'view archives' link in the lower right.

Genomics plc Signs Collaboration Agreement with Biogen

Genomics plc ("Genomics"), a leading analysis company developing algorithms, data resources and software solutions to uncover the relationships between genetic variation and human disease, recently announced that it has entered into a collaboration agreement with Biogen. The collaboration aims to refine drug target selection through the use of sophisticated analysis of human genetic data.Under the terms of the agreement, Biogen will leverage findings from Genomics' integrated database and state-of-the-art ...

Posted on: October 13, 2015
Improving Outcomes for Lymphoma and Melanoma

Genentech, a member of the Roche Group, announced results from the Phase III GADOLIN study showing that Gazyva (obinutuzumab) plus bendamustine followed by Gazyva alone provided significant benefit for people with indolent non-Hodgkin's lymphoma (NHL) that is refractory to Rituxan (rituximab)-based treatment. In the study, Gazyva plus bendamustine followed by Gazyva alone reduced the risk of disease worsening or death (progression-free survival [PFS]) by 45 percent compared to bendamustine alone. The ...

Posted on: October 12, 2015
UCI Researchers Find Biomarker for Autism That May Aid Diagnostics

By identifying a key signaling defect within a specific membrane structure in all cells, University of California, Irvine (UCI) researchers believe, they have found both a possible reliable biomarker for diagnosing certain forms of autism and a potential therapeutic target.J. Jay Gargus, MD, PhD, Ian Parker and colleagues at the UCI Center for Autism Research & Translation examined skin biopsies of patients with three very different genetic types of the disorder (fragile X syndrome and tuberous ...

Posted on: October 11, 2015
MDx at Home: Chemists Design Rapid, Simple, Inexpensive Tests Using DNA

Chemists at the University of Montreal used DNA molecules to developed rapid, inexpensive medical diagnostic tests that take only a few minutes to perform. Their findings, published in the Journal of the American Chemical Society, may aid efforts to build point-of-care devices for quick medical diagnosis of various diseases ranging from cancer to allergies, autoimmune diseases, sexually transmitted diseases (STDs), and many others. The new technology may also drastically impact global health, due to ...

Posted on: October 09, 2015
NovoPath Anatomic Pathology LIS Software Announces New Clinical Results Management Module

NovoPath Inc. introduces its Clinical Results Management module add-on to its NovoPath Anatomic Pathology (AP) Software to support the growing demand for AP and clinical results integration. This module employs NovoPath's IT expertise and understanding of lab processes and procedures to create an optimal solution to manage and integrate the anatomic and clinical pathology results into one integrated system. In addition, this module supports the seamless data exchange with clinical instruments."With this ...

Posted on: October 08, 2015
Roche NimbleGen Introduces Enhanced Whole Exome Sequencing Solution for Medical and Translational Research

Roche has announced the global launch of the SeqCap EZ MedExome Target Enrichment Kit, a comprehensive whole exome sequencing (WES) solution designed to increase the discovery and detection of human genetic variants associated with disease while reducing sequencing costs."Interest in this design from our customers worldwide led to initiation of an early product evaluation process resulting in more than 40 evaluations across 11 countries globally prior to launch," said Rebecca Selzer, president of Roche ...

Posted on: October 07, 2015
VolitionRx Receives CE Mark for NuQ Blood Assay for Detection of Colorectal Cancer

VolitionRx Limited has received the company's first CE Mark for its blood-based diagnostic assay, NuQX001S, for detection of colorectal cancer. The NuQ test utilizes the company's proprietary Nucleosomics technology platform, which identifies and analyses fragments of chromosomes, called nucleosomes, circulating within the blood for the presence of epigenetic cancer signals.The NuQX001S assay is the first to be CE Marked out of a suite of NuQ assays developed by VolitionRx targeting ...

Posted on: October 06, 2015
New NIH Grant to Fund Effort to Build Reproducible Assays to Model Autism

The National Institutes of Health has awarded a $13 million grant over five years to develop and disseminate new stem cell-based technologies and assays for studying autism spectrum disorder (ASD) and other mental health diseases to a consortium of researchers at the University of California, San Diego and the Salk Institute for Biological Studies, working in tandem with leaders in the biotechnology sector.Many mental health disorders, including ASD, are strongly influenced, sometimes exclusively, by ...

Posted on: October 05, 2015
Microbiome Implicated in Sickle Cell Disease, but Antibiotics Can Counter Its Effects

New research on sickle cell disease (SCD) has found that using antibiotics to deplete the body's microbiome may prevent acute sickle cell crisis and could offer the first effective strategy for warding off  the disease's long-term complications, such as organ failure. The study, conducted by scientists at Albert Einstein College of Medicine and Montefiore Health System, could also lead to better treatment for other inflammatory blood-vessel disorders including septic shock. The findings were ...

Posted on: October 04, 2015
Genomic Analysis for All Cancer Patients at Jefferson

Cancer medicine is moving toward understanding what drives each particular patient's cancer. But not every patient has had access to this level of individualized care. Today, Thomas Jefferson University announced its ability to provide routine genomic fingerprinting to cancer patients, giving patients and physicians the information they need to make the most appropriate treatment decisions based on each patient's individual cancer."At Jefferson genomic analysis - which gives us a clear view of a ...

Posted on: October 02, 2015
Oncotype DX Becomes Only Genomic Breast Cancer Test with Prospective Outcomes Data from Uniformly Treated Patients

Genomic Health Inc. has announced that results from four Oncotype DX breast cancer studies, including three large clinical outcomes studies in which the test was used to determine treatment, was presented this week at the 2015 European Cancer Congress (ECC 2015) in Vienna, Austria.Included in the ECC 2015 program was the first presentation of clinical outcomes results from the large, prospective Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, which was sponsored by the National ...

Posted on: October 01, 2015
Penn Team Pinpoints Immune Changes in Blood of Melanoma Patients on PD-1 Drugs That Put Potential Biomarker within Reach

A simple blood test can detect early markers of "reinvigorated" T cells and track immune responses in metastatic melanoma patients after initial treatment with the anti-PD-1 drug pembrolizumab, researchers from the Abramson Cancer Center of the University of Pennsylvania report in new research being presented at the inaugural CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference. The new findings give more insight into how the anti-PD-1 therapy, approved last year by the U.S. ...

Posted on: September 30, 2015
Dartmouth Investigators Study Impact of Shift in Testing Guidelines for Assessing HER2 Status in Breast Cancer Patients

 In a retrospective study, Dartmouth investigators led by Laura Tafe, MD, with colleague Jonathan Marotti, MD, and Pathology Chief Resident Kristen Muller, DO, found that a revision in 2013 by the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) of guidelines for evaluating the HER2 status of breast cancer had a significant impact on women's HER2 classification. Their findings, "Impact of the 2013 ASCO/CAP HER2 Guideline Updates at an Academic ...

Posted on: September 29, 2015
mproved Sensitivity with the New Protein and Phospholipid Removal Columns from Biotage

Biotage, a leading global supplier of solutions and technology for analytical, medicinal and peptide chemistry, is pleased to announce the extension of the ISOLUTE PLD+ protein and phospholipid removal product line to include the versatile tabless 1 mL column format, for the clean-up of blood based matrix samples for analysis by LC-MS/MS.ISOLUTE PLD+ 96-well plates and columns combine protein and phospholipid removal into a single product providing very effective and extremely simple sample ...

Posted on: September 28, 2015
ClearLight Diagnostics Licenses Intellectual Property Rights from Stanford University for Tissue Processing and Imaging Technologies CLARITY and COLM

ClearLight Diagnostics, a developer of new tools and technologies for the analysis and imaging of tissue samples, has signed an exclusive, worldwide license agreement with Stanford University for the intellectual property rights covering inventions relating to tissue processing and imaging. The licensed technologies involve CLARITY, a tissue "clarification" method that renders the tissue optically transparent, and COLM (CLARITY Optimized Light-sheet Microscopy), a new optics system for accelerating image ...

Posted on: September 27, 2015
View Archives

Back to Top

© 2015 Merion Matters

2900 Horizon Drive, King of Prussia PA 19406